北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer
作者: Wang, Xin1; Zhao, Jun1; Yang, Lu1; Mao, Li2; An, Tongtong1; Bai, Hua1; Wang, Shuhang1; Liu, Xuyi1; Feng, Guoshuang3; Wang, Jie1
关键词: ERCC1 ; RRM1 ; NSCLC ; Platinum-based chemotherapy
刊名: MEDICAL ONCOLOGY
发表日期: 2010-06-01
DOI: 10.1007/s12032-009-9239-3
卷: 27, 期:2, 页:484-490
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: MESSENGER-RNA EXPRESSION ; GEMCITABINE ; CISPLATIN ; SURVIVAL ; RRM1 ; CHEMOTHERAPY ; REPAIR ; LINES
英文摘要:

The goal of this study is to determine role of excision repair cross-complementing group 1 gene (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) expression in predicting response and survival in Chinese patients with advanced stage non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy. Formalin-fixed, paraffin-embedded biopsy tissues were retrospectively obtained from 124 advanced NSCLC patients. Protein expression levels of ERCC1 and RRM1 were determined by immunohistochemistry (IHC). Associations between expression of ERCC1 and RRM1 and clinic-pathologic parameters were analyzed. The study shows that ERCC1 and RRM1 expression was detected in 43 (35%) and 50 (40%) of the 124 tumor samples, respectively. Expression of ERCC1 and RRM1 was negatively associated with tumor response. Fifty-four percent patients whose tumors did not express ERCC1 had partial response (PR) compared to 33% whose tumors expressed the protein (P = 0.022). Similarly, 54% patients whose tumor did not express RRM1 had PR compared to 36% whose tumors expression the protein (P = 0.042). Further, patients whose tumors lacked of ERCC1 but not RRM1 expression had a longer median survival time than those tumors expressed ERCC1 (13.4 months versus 9.1 months; P = 0.006), which is independent of other prognostic factors (P = 0.0066). In conclusion, tumor ERCC1 expression is associated with tumor response and patients′ survival in Chinese advanced NSCLC patients treated with platinum-based regimen and may serve as a biomarker in predicting tumor response and clinical outcome in the patient population.

语种: 英语
所属项目编号: 2006AA02A401 ; 30772472 ; 2-013-39
项目资助者: National High Technology Research and Development Program of China ; Capital Development Foundation ; Peking University
WOS记录号: WOS:000277203200050
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/55932
Appears in Collections:北京大学临床肿瘤学院_胸部肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Thorac Med Oncol, Beijing 100036, Peoples R China
2.Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
3.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Biostat, Beijing 100036, Peoples R China

Recommended Citation:
Wang, Xin,Zhao, Jun,Yang, Lu,et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer[J]. MEDICAL ONCOLOGY,2010,27(2):484-490.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Wang, Xin]'s Articles
[Zhao, Jun]'s Articles
[Yang, Lu]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Wang, Xin]‘s Articles
[Zhao, Jun]‘s Articles
[Yang, Lu]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2018  北京大学医学部 - Feedback
Powered by CSpace